Back to

Ivan Ostojic

Partner, Zurich
Helps set new business models and pursue technology, digital, and analytics solutions to drive innovation, working across industries and as an advisor to technology-driven healthcare and life-science companies

About Ivan

Ivan leads McKinsey’s innovation work in Europe, the Middle East, and Africa, where he advises clients across a variety of sectors on strategic business models and organizational approaches that drive innovation. Ivan has deep expertise in leveraging digital solutions and advanced analytics to foster innovation at scale. Ivan often applies these approaches when advising clients in technology-driven industries such as pharmaceuticals, biotechnology, life sciences, chemicals, energy, and advanced industries.

Ivan also leads the firm’s emerging technology & future lab and business building work as part of the exponential innovation domain within our Pharmaceuticals & Medical Products Practice. When working with pharmaceutical companies in Europe and the United States, he helps executives achieve greater innovation across the value chain, including research, commercialization, and portfolio management. From digital and advanced analytics in R&D and medical affairs through enhanced customer experience design and new business building, Ivan helps clients transform how they work and deliver value.

Examples of his recent client work include the following:

  • designing a digital-innovation strategy for a large pharmaceutical company to improve solutions for patients and deliver a better experience for healthcare providers
  • developing an innovation strategy and digital-health transformation roadmap for a health-technology company, including setting up a new operating model, building necessary capabilities, and identifying supporting technologies
  • leading multiple projects to develop business models and launch early commercialization of new products and technologies for life-science and pharmaceutical companies
  • guiding a digital-transformation effort for a rare-disease pharmaceutical company, including developing a new digital-and-analytics strategy and launching a capability-building program for 100 key employees
  • directing innovation-transformation projects for life-science and other companies using big data and advanced analytics
  • directing an analytics transformation for a midsize pharmaceutical company, including setting up an agile lab and delivering relevant R&D use cases for patient segmentation and trial monitoring
  • building a “unicorn” scale-up factory to support an energy company launching disruptive businesses in an era of energy transition
  • leading a disruptive-technology assessment-and-evaluation initiative and creating a business-model-innovation and technology-commercialization roadmap for an industrial company

As an advocate for the transformative power of digital and analytics, Ivan has authored several articles pushing for greater innovation in medical affairs, R&D, and beyond. Before joining McKinsey, Ivan spent six years as a research scientist exploring neurological and hormonal regulation of aging and life span.

Published work

Scale or fail: How incumbents can industrialize new-business building,” McKinsey & Company, March 2021

How growth can help Europe’s companies face the coming economic crisis,” McKinsey & Company, May 2020

Unlocking the power of translational medicine,” McKinsey & Company, February 2020

A game plan for quantum computing,” McKinsey Quarterly, February 2020

Traditional company, new businesses: The pairing that can ensure an incumbent’s survival,” McKinsey & Company, June 2019

From product to customer experience: The new way to launch in pharma,” McKinsey & Company, August 2018

Medical affairs: Key imperatives for engaging and educating physicians in a digital world,” McKinsey & Company, March 2018

Past experience

FMI, Friedrich Miescher Institute for Biomedical research
Research associate

The Novartis Institutes for BioMedical Research (NIBR)
Research associate


FMI, University of Basel
PhD, biochemistry and molecular biology

ETH Zurich, Swiss Federal Institute of Technology
MSc, management, technology, and economics

University of Belgrade
MSc, molecular biology, physiology